You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: NeuroSigma, Inc. Topic: 101
DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Medosome Biotec, LLC Topic: NICHD
ABSTRACT SUMMARY Pyruvate dehydrogenase complex PDC deficiency PDCD is a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncated Treatment of PDCD remains a serious unmet challenge There has never been a controlled trial of any intervention for PDCD thus there is no proven therapy for affected patients Dichloroacetate DCA ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Novici Biotech LLC Topic: NHLBI
DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Medosome Biotec, LLC Topic: NIAMS
DESCRIPTION provided by applicant The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders However inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy A few therapies are finally edging towards approval but it has become ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: GINER INC Topic: NICHD
DESCRIPTION provided by applicant Non Invasive Highly Specific Detection of Oxytocin in Biological Fluids Oxytocin a neuropeptide hormone plays an important role in a variety of complex social behaviors including affiliation sexual behavior and aggression It is best known for its role to facilitate the birth process through induction of myometrial muscle contractions However recent studi ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Nanoliter electron paramagnetic resonance sensor based on diamond nanophotonics: a new tool for biomarker monitoringSBC: ODMR Technologies, Inc Topic: 400
DESCRIPTION provided by applicant ODMR Technologies Inc together with Victor Acostaandapos s group at University of New Mexico is developing a nanophotonic platform capable of uniquely detecting minute quantities of biomolecules The specific detection of biomolecules plays a central role in modern life science including cell systems biology high throughput drug scre ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: VIROGENICS, INC. Topic: NIAID
DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: SignalRx Pharmaceuticals Inc. Topic: NCI
PARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: On Target Therapeutics, LLC Topic: 106
DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: ZMK Medical Technologies, Inc. Topic: 102
This Phase II proposal is a continuation of our successful Phase I grant whose overarching goal is to develop a more robust and accurate method for the deformable fusion of pre operative magnetic resonance images MRI and intra procedure trans rectal ultrasound TRUS images to guide prostate biopsy Prostate cancer is a major cause of death in the U S and biopsy is the gold standard for its dia ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health